Login to Your Account

Clinic roundup

Wednesday, May 7, 2014

Rhythm Pharmaceuticals Inc., of Boston, presented phase II results at the Digestive Disease Week conference in Chicago showing that relamorelin, administered twice daily for four weeks in patients with moderate to severe gastroparesis, significantly improved gastric emptying, significantly reduced vomiting and, in a large subgroup (about 60 percent of patients) with vomiting at baseline, significantly improved a composite symptom score comprising nausea, abdominal pain, bloating and early satiety.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription